Skip to content

Nuvation Bio NUVB Unrealized Gain (Loss), Foreign Currency Transaction, before Tax

Unrealized Gain (Loss), Foreign Currency Transaction, before Tax at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
-$190K-185%

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.1B+150%
Enterprise value$2.03B+154%
P/S14.7×-62.0×

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossUnrealized.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's unrealized gain (loss), foreign currency transaction, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's unrealized gain (loss), foreign currency transaction, before tax?
Nuvation Bio (NUVB) reported unrealized gain (loss), foreign currency transaction, before tax of $21K in Q1 2026.
How has Nuvation Bio's unrealized gain (loss), foreign currency transaction, before tax changed year-over-year?
Nuvation Bio's unrealized gain (loss), foreign currency transaction, before tax increased by 108.5% year-over-year, from -$248K to $21K.
What does unrealized gain (loss), foreign currency transaction, before tax mean?
Represents the impact of exchange rate fluctuations on monetary assets and liabilities denominated in foreign currencies that have not yet been settled. It serves as a non-cash adjustment to reconcile net income to operating cash flow.